Study Evaluating Management of Patients With Moderate and Severe Psoriasis

Wyeth is now a wholly owned subsidiary of Pfizer469 enrolled

Overview

This is an observational, naturalistic, multicenter, retrospective study to describe the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs in usual clinical practice in Spain.

Study Type

OBSERVATIONAL

Enrollment

469

Conditions

Psoriasis

Interventions

Clinical record reviewOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Main Inclusion Criteria: ·Over 18 years of age.·Diagnosed with moderate or severe psoriasis.·Initiated treatment with topical and/or systemic treatment between two and five years before enrollment in the study. ·Has a clinical record at the dermatologist office. Main Exclusion Criteria: ·Currently participating in a clinical study. ·Clinical record lacks minimum data required for observational analysis.

Locations (1)

Unnamed facility

Madrid, Madrid, Spain

Outcomes

Primary Outcomes

Descriptive analysis of the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs including sequence, doses and duration of treatment.

Time frame: 4 months

Secondary Outcomes

Comparison of therapeutic management depending on patients' disease severity, using absolute and relative frequencies for qualitative variables and centralization and dispersion measures (mean, SD, median, minimum, maximum..) for quantitative variables.

Time frame: 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.